
GRI Valuation
GRI Bio Inc
GRI Relative Valuation
GRI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GRI is overvalued; if below, it's undervalued.
Historical Valuation
GRI Bio Inc (GRI) is now in the Fair zone, suggesting that its current forward PS ratio of 1.70 is considered Fairly compared with the five-year average of -0.19. The fair price of GRI Bio Inc (GRI) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:1.70
Fair
-0.43
PE
1Y
3Y
5Y
Trailing
Forward
0.05
EV/EBITDA
GRI Bio Inc. (GRI) has a current EV/EBITDA of 0.05. The 5-year average EV/EBITDA is 0.02. The thresholds are as follows: Strongly Undervalued below -0.23, Undervalued between -0.23 and -0.11, Fairly Valued between 0.14 and -0.11, Overvalued between 0.14 and 0.27, and Strongly Overvalued above 0.27. The current Forward EV/EBITDA of 0.05 falls within the Historic Trend Line -Fairly Valued range.
0.07
EV/EBIT
GRI Bio Inc. (GRI) has a current EV/EBIT of 0.07. The 5-year average EV/EBIT is 0.03. The thresholds are as follows: Strongly Undervalued below -0.28, Undervalued between -0.28 and -0.12, Fairly Valued between 0.19 and -0.12, Overvalued between 0.19 and 0.34, and Strongly Overvalued above 0.34. The current Forward EV/EBIT of 0.07 falls within the Historic Trend Line -Fairly Valued range.
1.70
PS
GRI Bio Inc. (GRI) has a current PS of 1.70. The 5-year average PS is 0.02. The thresholds are as follows: Strongly Undervalued below -0.32, Undervalued between -0.32 and -0.15, Fairly Valued between 0.18 and -0.15, Overvalued between 0.18 and 0.35, and Strongly Overvalued above 0.35. The current Forward PS of 1.70 falls within the Strongly Overvalued range.
-0.42
P/OCF
GRI Bio Inc. (GRI) has a current P/OCF of -0.42. The 5-year average P/OCF is -0.19. The thresholds are as follows: Strongly Undervalued below -0.77, Undervalued between -0.77 and -0.48, Fairly Valued between 0.10 and -0.48, Overvalued between 0.10 and 0.39, and Strongly Overvalued above 0.39. The current Forward P/OCF of -0.42 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
GRI Bio Inc. (GRI) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
GRI Bio Inc (GRI) has a current Price-to-Book (P/B) ratio of 1.28. Compared to its 3-year average P/B ratio of -359.91 , the current P/B ratio is approximately -100.36% higher. Relative to its 5-year average P/B ratio of -359.91, the current P/B ratio is about -100.36% higher. GRI Bio Inc (GRI) has a Forward Free Cash Flow (FCF) yield of approximately -214.43%. Compared to its 3-year average FCF yield of -492.53%, the current FCF yield is approximately -56.46% lower. Relative to its 5-year average FCF yield of -492.53% , the current FCF yield is about -56.46% lower.
1.28
P/B
Median3y
-359.91
Median5y
-359.91
-214.43
FCF Yield
Median3y
-492.53
Median5y
-492.53
Competitors Valuation Multiple
The average P/S ratio for GRI's competitors is 2.98, providing a benchmark for relative valuation. GRI Bio Inc Corp (GRI) exhibits a P/S ratio of 1.70, which is -42.86% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GRI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GRI in the past 1 year is driven by Unknown.
People Also Watch

UBXG
U-BX Technology Ltd
2.120
USD
+0.47%

SOAR
Volato Group Inc
1.670
USD
+9.15%

CREG
Smart Powerr Corp
1.180
USD
-3.28%

BLBX
Blackboxstocks Inc
9.500
USD
+3.15%

FATBB
FAT Brands Inc
2.430
USD
0.00%

SMX
SMX (Security Matters) PLC
2.020
USD
-16.87%

XHG
XChange TEC.INC
0.930
USD
-3.13%

BKYI
BIO-Key International Inc
0.780
USD
+1.30%

ALZN
Alzamend Neuro Inc
2.530
USD
-3.07%
FAQ
Is GRI Bio Inc (GRI) currently overvalued or undervalued?
GRI Bio Inc (GRI) is now in the Fair zone, suggesting that its current forward PS ratio of 1.70 is considered Fairly compared with the five-year average of -0.19. The fair price of GRI Bio Inc (GRI) is between to according to relative valuation methord.







